Efficacy and Safety Study of Second-Line Prolgolimab Monotherapy or in Combination With Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma

Prolgolimab is an anti-PD-1 inhibitor that has previously been shown to be effective and safe for the treatment of patients with melanoma. Given the mechanism of action, it is expected to be effective in patients with classical Hodgkin lymphoma (cHL).
The use of PD-1 inhibitors in 2nd line treatment, as part of PET-adapted monotherapy/combination therapy, has already demonstrated a favorable toxicity profile, as well as a high efficacy, which may lead to increased survival of patients with r/r cHL. It has been demonstrated that long-term disease remission can be achieved after PD-1 inhibitor therapy, even in a group of heavily pretreated patients with relapsed/refractory cHL. The use of prolgolimab as part of PET-adapted therapy strategy in this study may allow to achieve a prolonged remission in patients with cHL who are highly sensitive to immunotherapy while omitting the autologous stem cell transplantation.

Start Date19 Apr 2023

Sponsor / Collaborator-

CTRI/2022/12/048223

/ Active, not recruitingPhase 3

A Double-Blind Placebo-Controlled ComparativeRandomized Clinical Study of the Efficacy and Safety ofBCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-LineTreatment in Subjects with Unresectable/MetastaticMelanoma - OCTAVA

Start Date02 Jan 2023

Sponsor / Collaborator

Biocad CJSC

NCT05732805

/ Active, not recruitingPhase 3

A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with unresectable or metastatic melanoma.

Start Date02 Aug 2022

Sponsor / Collaborator

Biocad Medical, Inc.

100 Clinical Results associated with Prolgolimab

100 Translational Medicine associated with Prolgolimab

100 Patents (Medical) associated with Prolgolimab

Literatures (Medical) associated with Prolgolimab

30 Jul 2026·Arkhiv patologii

Morphological features of immune-related cutaneous adverse events associated with anti-PD-1/PD-L1 cancer immunotherapy

Article

Author: Syryseva, A.Yu. ; Bobyreva, A.A. ; Shatokhina, E.A. ; Danilova, N.V. ; Pokataev, I.A.

Objective. To study the morphological patterns of immune-related cutaneous lesions (irCLs) that occur during antitumor immunotherapy in cancer patients. Material and methods. The study included 48 patients with the following nosology: malignant neoplasms of the skin and soft tissues — 20 patients (41.7%), malignant neoplasms of the genitourinary system — 13 (27%), malignant neoplasms of the lungs and bronchi — 9 (18.8%), malignant neoplasms of the upper respiratory tract — 5 (10.4%), malignant neoplasms of the gastrointestinal tract — 1 (2.1%), with immune-mediated skin lesions during treatment with pembrolizumab — 25 (52.1%), nivolumab — 18 (37.5%), prolgolimab — 4 (8.3%), avelumab — 1 (2.1%). Results. Among the irCLs in the study cohort, lichenoid — 14 (29.2%) cases and psoriasiform — 11 cases (22.9%) were predominant, while other morphological variants were significantly less common. IrCL morphologically mimic classic dermatoses, but have distinctive features indicating their drug-induced, immune-related nature. Conclusion. The study demonstrated that irCLs are clinically significant complications of PD-1/PD-L1 inhibitor therapy. Histological analysis confirmed their immunoinflammatory nature and revealed characteristic morphological changes, emphasizing the importance of routine skin biopsies for optimal patient management.

01 May 2026·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Efficacy of immune checkpoint inhibitors in the first line therapy of non-squamous non-small cell lung cancer: A systematic review and network meta-analysis

Review

Author: Mironenko, Olga ; Fedyanin, Mikhail ; Zhukov, Nikolai ; Sapozhnikov, Kirill ; Sableva, Natalia ; Moiseenko, Fedor ; Tolkacheva, Daria ; Lazarev, Andrei

AIM:

By 2026, several PD-1/PD-L1 antibodies were approved by FDA, EMA and non-EU Eastern European countries for the first-line therapy in advanced non-squamous non-small cell lung cancer (nsNSCLC) without EGFR mutations or ALK alterations. This study aimed to compare overall (OS) and progression-free (PFS) survival among anti-PD-1/PD-L1-containing regimens and to evaluate the immunotherapy effect modification due to PD-L1 expression.

METHODS:

A systematic search in MEDLINE and Embase on December 23, 2025 identified 15 Phase III randomized clinical trials involving adults with advanced nsNSCLC treated with therapies containing prespecified anti-PD-1/PD-L1 agents. Bayesian multilevel network meta-regressions with M-splines were estimated for OS and PFS, incorporating covariates for PD-L1 expression (TPS <1% versus ≥1%) and its interaction with the treatment class (anti-PD-1/PD-L1-based regimens versus chemotherapy ± bevacizumab).

RESULTS:

Regardless of PD-L1 expression, treatments with the highest probability of being the best (SUCRA) by OS are prolgolimab + chemotherapy, pembrolizumab + chemotherapy and cemiplimab + chemotherapy (SUCRA 0.80-0.94), by PFS nivolumab + bevacizumab + chemotherapy and atezolizumab + bevacizumab + chemotherapy (SUCRA 0.91-0.96). The hazard ratio for the interaction between PD-L1-negative status and anti-PD-1/PD-L1-containing therapy was 1.09 (95% CrI, 0.95-1.25) for OS and 1.41 (95% CrI, 1.16-1.71) for PFS.

CONCLUSION:

For advanced nsNSCLC patients, irrespective of PD-L1 expression, prolgolimab, pembrolizumab or cemiplimab, each combined with chemotherapy, are most efficacious by OS; nivolumab or atezolizumab combined with bevacizumab and chemotherapy demonstrate the highest PFS. PD-L1 expression does not modify the effect of examined immunotherapy options on OS, though the opposite is true for PFS.

01 Dec 2025·JCO Precision Oncology

Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer

Article

Author: Dzhumabaev, Khasan ; Fedyanin, Mikhail ; Aliev, Vyacheslav ; Tryakin, Alexey ; Ivanov, Maxim ; Polynovsky, Andrey ; Mamedli, Zaman ; Prokopiev, Aleksander ; Stroganova, Anna ; Aniskin, Aleksander ; Zagidullina, Albina ; Kuznetsova, Olesya ; Drobot, Natalia ; Karasev, Ivan

PURPOSE:

Although adjuvant chemotherapy is standard for locally advanced colon cancer, defective mismatch repair (dMMR)/microsatellite instability (MSI) tumors show high sensitivity to immune checkpoint inhibitors. We aimed to investigate the efficacy of the PD-1 inhibitor prolgolimab in this setting.

METHODS:

We conducted phase II nonrandomized open-label clinical trial (ClinicalTrials.gov identifier: NCT06428487 ) in patients with locally advanced colorectal cancer (CRC) and dMMR/MSI. Prolgolimab (1 mg/kg) was administered once every 2 weeks, and surgery was performed after 6 months of immunotherapy. In case of surgical treatment refusal, the systemic treatment proceeded for 1 year. The primary end point was the rate of pathologic complete response (pCR, in operated cases) + clinical complete response (cCR, in nonoperated cases). Secondary end points included pCR, major pathologic response (MPR), objective response (ORR) rates, safety, disease-free survival (DFS), and overall survival.

RESULTS:

Of the 30 enrolled, 26 (86.6%) patients underwent surgery after the end of immunotherapy. The study met its primary end point, with 17 (56.7%) of 30 patients achieving pCR (n = 16) + cCR (n = 1 as nonoperated case). According to histologic examination, an MPR (TRG 1-2) was observed in 21 (80.8%) of 26 patients, including 16 (61.6%) patients with pCR. Radiographic ORR was 89.7%, and cCR was observed in six cases (20.7%, five patients underwent surgery further). Three patients with low rectal primary tumors refused to undergo a surgical treatment. The median follow-up was 19 months (range, 13-32). The 18-month DFS was 90%: two progressions and one unrelated death were detected. Grade 3-4 immune-related adverse effects were recorded in one (3.3%) patient.

CONCLUSION:

The use of prolgolimab in locally advanced dMMR/MSI CRC is associated with high rates of pCR and cCR, allowing for further exploration of organ-sparing approaches in these patients.

News (Medical) associated with Prolgolimab

27 Jul 2022

·www.prnewswire.com

Cervical Cancer Therapeutics Epidemiology & Pipeline Analysis 2017-2027

DUBLIN, July 27, 2022 /PRNewswire/ -- The "Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering. The cervical cancer portfolio contains a total of 169+ assets that are in various phases of development. Most industry-sponsored drugs in active clinical development for cervical cancer are in the Phase II stage. The distribution of the pipeline drugs across Phase I-IV is dominated by Phase II (35.5%), followed by Phase I (31.36%), and then Phase III (7.10%). Cervical Cancer Therapeutics: Clinical Trials Scenario The clinical trial portfolio contains 282+ trials in various phases of development. The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with three drugs in the NDA/BLA stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of problems for cervical cancer have been in the early and mid-phases of development, with 94% of issues in Phase I-II and only 6% in Phase III-IV. The U.S. has a substantial lead in the number of cervical cancer clinical trials globally. The U.K. leads the primary European markets, while China has the top spot in Asia. Based on the efficacy demonstrated with pembrolizumab and the significant role of PD-L1 in cervical cancer, various anti-P.D.-(L)1 agents are currently under investigation as first-line therapies in cervical cancer. For instance, Atezolizumab and prolgolimab (BCD-100) combined with chemotherapy with or without bevacizumab and pembrolizumab with chemoradiotherapy are ongoing. In addition, several trials are examining novel combinations in this space. According to estimates, the diagnosed incident cases of cervical cancer were high in China, followed by the U.S. and Japan in 2020. The increasing prevalence of HIV (Human Immunodeficiency Virus) in women is driving the growth of the cervical cancer drugs market. Women with HIV positive have a greater risk of cervical cancer than the general population. Nearly 18 million women have tested HIV positive globally; HIV weakens the immune system, which increases the likelihood of cervical cancer. Surgery is the standard of care for the treatment of early-stage, while chemoradiation is the most common treatment modality for locally advanced disease. In the U.S., the approvals of Keytruda as first-line therapy and Tivdak as second-line therapy in 2021 wholly altered the treatment paradigm for recurrent and distally metastatic disease. Before the approval of Keytruda in the first line, patients received chemotherapy with Avastin, which remains the treatment of choice outside the U.S. MARKET TRENDS & DRIVERS Early Detection of Disease: More than 90% of cervical malignancies occur due to HPV infection (human papillomavirus), which can be diagnosed through smear screening. The Pap smear test, the most effective tool for diagnosing HPV in the early stage, is the most revenue-generating segment. Increasing Prevalence of Cervical cancer: The market study has been witnessing considerable growth, attributed to the increasing prevalence of cervical cancer among women worldwide. In 2018, an estimated 570 000 women were diagnosed with cervical cancer worldwide, and about 311 000 women died due to improper detection at the early stages of the disease. MARKET SEGMENTATION Drug Class: Chemotherapeutic drugs are expected to dominate the global cervical cancer therapeutics market. However, the targeted therapies are expected to be the fastest-growing segment during the forecast period. Recently approved biological drugs such as Keytruda (pembrolizumab) and Tivdak (tisotumab-vedotin-tftv) are expected to drive the targeted therapies segment during the forecast period. Histology type: Among the histology type, Squamous cell Carcinoma is expected to account for a significant share of the global cervical cancer therapeutics market. However, Adenocarcinoma is the fastest-growing segment during the forecast period due to its aggressive nature. Age Group: Among the Age group, women aged 50 years are expected to account for a significant portion of the global cervical cancer therapeutics market share. However, women between the age of 30 - 49 years are expected to be the fastest-growing segment during the forecast period. Distribution type: Among the distribution type, Retail & Specialty pharmacy services are expected to dominate the cervical cancer therapeutics market. According to the National Comprehensive Cancer Network Specialty Pharmacy Task Force, more than 80% of managed care organizations reported contracting with specialty pharmacy providers for their oncology business, and 51.4% reported using a single, preferred specialty provider for all limited-distribution drugs. Geography: The U.S. dominates the cervical cancer therapeutics market due to the rise in the healthcare affordability in the U.S., rise in the knowledge and rise in the awareness amongst the people, and rises in the technological advancement in this region. However, China is expected to grow faster with a high CAGR in the cervical cancer drug market due to a rise in healthcare access and quality, increased awareness about disease management, and rising healthcare expenditure. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter the therapeutic landscape in this region. COMPETITIVE SCENARIO The cervical cancer treatment market is dominated by many companies offering generic drugs and particular pharma/biotech companies offering patented/commercial drugs for treating cervical cancer. The U.S. Food and Drug Administration (FDA) approved the antiangiogenic agent bevacizumab (Avastin) to treat persistent, recurrent, or metastatic cervical cancer in 2014. This marked the arrival of biologics in this treatment landscape. Avastin was approved in Europe and Japan in 2015 and 2016, respectively. The FDA approved Keytruda (pembrolizumab) in 2018 and Tivdak (tisotumab-vedotin-tftv) in 2021 to treat cervical cancer. Although generic products continue to capture significant market share, the arrival of biologics and other targeted therapies indicates a paradigm shift in this therapeutic space through the forecast period. REPORT COVERAGE Detailed overview of cervical cancer, including disease definition, classification, diagnosis, and treatment pattern. Overview of the global trends of cervical cancer in the eight major markets (8MM) Historical, current, and projected patient pool of cervical cancer in the eight primary markets (8MM) for 2018-2027. Age group, Histology, Drug Class, and Drug Distribution type segmentation of cervical cancer in the eight major markets (8MM) Market Share of the market players, Company profiles, product specifications, and competitive landscape. Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints. Detailed overview of therapeutics pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for cervical cancer across all clinical stages. Coverage of dormant and discontinued pipelines projects along with the reasons across cervical cancer Coverage of significant milestones (products approvals/launch timelines, clinical trial result publication, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the cervical cancer space. Key Vendors: Seagen Inc Merck Roche Pfizer Sanofi/Regeneron Lee's Pharma/Sorrenti Akesobio HengRui Medicine Co., Ltd Henlius Biotech Biocad Advenchen Laboratories EXELIXIS Novertis GSK Zeria Pharmaceuticals Other Prominent Vendors Innovent Biologics Clovis Oncology IOVANCE Biotherapeutics Genor Biopharma Co., LTD Agenusbio Qilu Pharmaceutical Astrazeneca Puma Biotechnology Genmab Takeda Incyte Corp BioAtla, Inc. Helsinn Healthcare SA Qilu Pharmaceutical BeiGene Key Topics Covered: Chapter 1: Cervical Cancer Overview Cervical Cancer - An Overview Chapter 2: Cervical Cancer Epidemiology & Overview 8Mm: Historic & Projected Volume of Incidence & Prevalence of Cervical Cancer 8Mm: Comparative Analysis of Incidence & Prevalence of Cervical Cancer 8Mm: Historic & Projected Volume of Incidence of Cervical Cancer Cases by Age Group 8Mm: Comparative Analysis of Incidence of Cervical Cancer Cases by Age Group Chapter 3: Cervical Cancer Market Size & Overview 8Mm: Historic & Projected Revenue of Cervical Cancer 8Mm: Historic & Projected Revenue of Cervical Cancer Snapshot 8Mm: Historic & Projected Revenue Segmentation by Age Group, Histology Type, Drug Class & Distribution Type Chapter 4: Cervical Cancer Marketed Drugs Overview Cervical Cancer Marketed Drugs - An Overview Cervical Cancer Marketed Drugs - Summary Chapter 5: Cervical Cancer Pipeline Drugs Overview Cervical Cancer Pipeline Drugs - An Overview Cervical Cancer Pipeline Drugs - Snapshot Cervical Cancer Pipeline Drugs Overview & Snapshot - by Disease Type Cervical Cancer Pipeline Drugs Overview & Snapshot - by Development Phase Cervical Cancer Pipeline Drugs Overview & Snapshot - by Route of Administration Cervical Cancer Pipeline Drugs Overview & Snapshot - by Mechanism of Action Cervical Cancer Pipeline Drugs Overview & Snapshot - by Molecule Type Cervical Cancer Pipeline Drugs Overview & Snapshot - by Geography Type Chapter 6: Cervical Cancer Clinical Trials Overview Cervical Cancer Clinical Trials Overview Snapshot Cervical Cancer Clinical Trials Overview - by Recruitment Status Cervical Cancer Clinical Trials Overview - by Product Type Cervical Cancer Clinical Trials Overview - by Route of Administration Cervical Cancer Clinical Trials Overview - by Molecule Type Cervical Cancer Clinical Trials Overview - by Geography Type Chapter 7: Cervical Cancer Market Dynamics Cervical Cancer Treatment Market Drivers Cervical Cancer Treatment Market Constraints Cervical Cancer Treatment Market Trends Chapter 8: Cervical Cancer Competitive Landscape Cervical Cancer Competitive Landscape - Marketed Drugs Key Company Profiles Competitive Scenario of Cervical Cancer Treatment Market Other Prominent Company Profiles Key Company Overviews Cervical Cancer Competitive Landscape - Pipeline Drugs Key Emerging Company Profiles Key Emerging Company Overviews Other Prominent Company Profiles Chapter 9: Cervical Cancer Miscellaneous Key Tentative Drug Approvals Timeline Key Regulatory Designations Key Milestones Deals & Collaborations Potential Trial Head-To-Head Comparison Inactive/Discontinued/Dormant Products Unmet Needs & Strategic Recommendations For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Prolgolimab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Uterine Cervical Cancer	Phase 3	China	Shanghai Pharmaceuticals Holding Co., Ltd.	20 Jul 2022
Metastatic melanoma	Phase 3	Russia	Biocad CJSC	01 Feb 2022
Unresectable Melanoma	Phase 3	Russia	Biocad CJSC	01 Feb 2022
Advanced Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	China	Sph Biocad Hk Ltd.	13 Sep 2021
Advanced Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	China	Biocad CJSC	13 Sep 2021
Advanced Cervical Carcinoma	Phase 3	United States	Biocad CJSC	01 Oct 2019
Advanced Cervical Carcinoma	Phase 3	China	Biocad CJSC	01 Oct 2019
Advanced Cervical Carcinoma	Phase 3	Russia	Biocad CJSC	01 Oct 2019
Advanced Cervical Carcinoma	Phase 3	Turkey	Biocad CJSC	01 Oct 2019
Non-squamous non-small cell lung cancer	Phase 3	United States	Biocad CJSC	01 Jun 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05732805 (OCTAVA, ASCO2026)	Phase 3	Unresectable Melanoma First line	271	nurulimab + prolgolimab	jcjgtxdnww(acwdregyox) = felsxwwyaq vllcixxomz (isudjajjzi, 8.4 - NA) View more	Positive	29 May 2026
				prolgolimab	jcjgtxdnww(acwdregyox) = zkqcgmplaa vllcixxomz (isudjajjzi, 4.2 - 14.8) View more
NCT05732805 (OCTAVA, ASCO2025)	Phase 3	Metastatic melanoma First line	-	Prolgolimab + Nurulimab	tfwjqqzipq(thmdiuthyc): HR = 0.58 (95% CI, 0.38 - 0.9), P-Value = 0.015	Positive	30 May 2025
				Nivolumab 1mg/kg + Ipilimumab 3mg/kg
ASCO2025	Phase 1/2	Non-Small Cell Lung Cancer activating mutations \| PD-L1 expression	239	ICI (pembrolizumab and bioanalogues, atezolizumab, nivolumab or prolgolimab)	qwjdrzjsdl(qbotzbzktu) = tcnvdpfmfs zrvocjwqir (ivvdebvftz )	-	30 May 2025
NCT05757466 (PROLGO-HL, EBMT2025)	Phase 2	Classical Hodgkin's Lymphoma Second line	24	Prolgolimab 1 mg/kg	gkfzffeuyd(hmncfkxvwg) = rdqkuxtbje lraofhwntg (jvhvynoefr ) View more	Positive	30 Mar 2025
NCT03912389 (DOMAJOR, Pubmed \| Eur J Cancer)	Phase 3	Advanced Lung Non-Squamous Non-Small Cell Carcinoma First line PD-L1	292	Prolgolimab + Pemetrexed + Platinum-based chemotherapy	quokzpftod(ydsfrmyiym) = qrcvsmszsx zvvfmhzhqj (qgwstnmxqd, 22.28 - NA) View more	Positive	01 Feb 2025
				Placebo + Pemetrexed + Platinum-based chemotherapy	quokzpftod(ydsfrmyiym) = ltsfugwftd zvvfmhzhqj (qgwstnmxqd, 11.73 - 19.15) View more
NCT03912389 (BCD-100-3 \| DOMAJOR, WCLC2024) Manual	Phase 3	Non-squamous non-small cell lung cancer First line EGFR \| ALK \| PD-L1	291	Prolgolimab + Pemetrexed + Platinum drug	gqvymoxftt(qwetptbryy) = puwvvytftl rsxwqeatzp (otscafosym, 22.28 - NA) View more	Positive	09 Sep 2024
				Placebo + Pemetrexed + Platinum drug	gqvymoxftt(qwetptbryy) = yelahqqgvz rsxwqeatzp (otscafosym, 11.73 - 19.15) View more
NCT05783882 \| NCT03269565 (BCD-100-2 \| MIRACULUM, Pubmed \| Front Oncol) Manual	Phase 3	Metastatic melanoma First line	175	Prolgolimab 250 mg Q3W	rkqmcigsha(tqudpfyuvo) = gsguvcnbwn pkftukclky (ufxbzrbhwu, 24.8 - 42.8)	Positive	04 Sep 2024
				Prolgolimab 1 mg/kg Q2W	rkqmcigsha(tqudpfyuvo) = wtfluphvzk pkftukclky (ufxbzrbhwu, 21.3 - 46.0)
NCT06428487 (ESMO_GI 12024 \| ESMO_GI 22024) Manual	Phase 2	Microsatellite instability-high colorectal cancer Neoadjuvant MSI/dMMR	26	Prolgolimab 1 mg/kg	nnyhgqabgl(pcxrubaoss) = zjhnxnjggr avinqmknta (xwyofikxbu ) View more	Positive	27 Jun 2024
EHA2023	Not Applicable	Classical Hodgkin's Lymphoma	4	prolgolimab	scakibjcoc(lojyhdjdhv) = <1% zkycnyacco (kfwkkmpqve ) View more	-	08 Jun 2023
NCT03912402 (CAESURA, ASCO 12023 \| ASCO 22023) Manual	Phase 2	Advanced Cervical Carcinoma	58	prolgolimab+paclitaxel+platinum drug+bevacizumab	pxclgnihfo(yrojzlnhoe) = hjtytfwota azcamyqorj (iylslyvgfq ) View more	Positive	31 May 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis